HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Noriyuki Masuda Selected Research

ASP6432

6/2019Modulation of urinary frequency via type 1 lysophosphatidic acid receptors: Effect of the novel antagonist ASP6432 in conscious rats.
3/2019ASP6432, a type 1 lysophosphatidic acid receptor antagonist, reduces urethral function during urine voiding and improves voiding dysfunction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Noriyuki Masuda Research Topics

Disease

46Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2021 - 06/2005
23Neoplasms (Cancer)
11/2018 - 04/2004
19Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2018 - 01/2003
14Adenocarcinoma of Lung
11/2019 - 03/2010
14Lung Neoplasms (Lung Cancer)
04/2018 - 06/2005
9Neoplasm Metastasis (Metastasis)
11/2018 - 04/2004
9Adenocarcinoma
04/2018 - 11/2006
9Carcinoma (Carcinomatosis)
12/2015 - 09/2009
8Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2021 - 11/2006
7Interstitial Lung Diseases (Interstitial Lung Disease)
01/2019 - 09/2008
6Neutropenia
01/2018 - 01/2003
4Disease Progression
01/2018 - 12/2006
4Febrile Neutropenia
10/2017 - 04/2012
4Small Cell Carcinoma
01/2015 - 11/2007
3Infections
08/2015 - 04/2012
3Leukopenia
08/2015 - 01/2003
3Pneumonia (Pneumonitis)
04/2012 - 09/2008
2Urologic Diseases (Urinary Tract Disease)
06/2019 - 03/2019
2Pain (Aches)
01/2018 - 01/2016
2Pneumothorax
05/2017 - 01/2017
2Hypertension (High Blood Pressure)
01/2017 - 07/2011
2Thrombocytopenia (Thrombopenia)
01/2017 - 01/2003
2Bronchiectasis
01/2017 - 07/2011
2Hypercapnia
12/2016 - 01/2015
2Chronic Obstructive Pulmonary Disease (COPD)
01/2015 - 04/2009
2Diarrhea
03/2012 - 10/2008
2Anemia
06/2009 - 01/2003
1COVID-19
01/2023
1Urinary Bladder Neck Obstruction (Bladder Neck Obstruction)
07/2022
1Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
06/2019
1Drug-Related Side Effects and Adverse Reactions
04/2019
1Brain Neoplasms (Brain Tumor)
04/2019
1Pleural Effusion (Pleural Effusions)
01/2019
1Pulmonary Edema
01/2019
1Hyperplasia
01/2018

Drug/Important Bio-Agent (IBA)

14ErbB Receptors (EGF Receptor)IBA
01/2021 - 08/2005
12amrubicinIBA
01/2021 - 06/2005
10Irinotecan (Camptosar)FDA LinkGeneric
01/2017 - 06/2005
9Carboplatin (JM8)FDA LinkGeneric
01/2020 - 11/2010
8Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2021 - 02/2010
8PlatinumIBA
01/2018 - 06/2005
8Gefitinib (Iressa)FDA Link
01/2015 - 08/2005
7Cisplatin (Platino)FDA LinkGeneric
01/2020 - 01/2011
7Docetaxel (Taxotere)FDA Link
01/2020 - 06/2005
7Tyrosine Kinase InhibitorsIBA
01/2019 - 02/2010
7Proteins (Proteins, Gene)FDA Link
01/2017 - 02/2010
6Paclitaxel (Taxol)FDA LinkGeneric
01/2020 - 06/2005
5130-nm albumin-bound paclitaxelIBA
01/2018 - 05/2014
5Pemetrexed (MTA)FDA Link
05/2017 - 01/2012
4Monoclonal AntibodiesIBA
04/2018 - 07/2010
3CrizotinibIBA
09/2019 - 01/2019
3AntigensIBA
04/2018 - 01/2012
3NestinIBA
01/2017 - 04/2011
3AutoantibodiesIBA
01/2015 - 06/2012
3ParaffinIBA
12/2011 - 02/2010
3Formaldehyde (Formol)FDA Link
12/2011 - 02/2010
3Topotecan (Hycamtin)FDA LinkGeneric
10/2011 - 01/2003
3GemcitabineFDA Link
01/2011 - 06/2005
2Adrenergic Receptors (Adrenergic Receptor)IBA
07/2022 - 05/2016
2Midodrine (Midon)FDA LinkGeneric
07/2022 - 05/2016
2Immunoglobulin G (IgG)IBA
01/2021 - 11/2006
2Anaplastic Lymphoma KinaseIBA
09/2019 - 01/2016
2ASP6432IBA
06/2019 - 03/2019
2alectinibIBA
04/2019 - 01/2016
2NivolumabIBA
11/2018 - 01/2017
2Indicators and Reagents (Reagents)IBA
04/2018 - 02/2013
2nedaplatinIBA
01/2018 - 12/2015
2Bevacizumab (Avastin)FDA Link
01/2018 - 12/2012
2SteroidsIBA
01/2017 - 12/2016
2Cadherins (E-Cadherin)IBA
01/2017 - 11/2006
2Aminophylline (Carine)FDA LinkGeneric
12/2016 - 01/2015
2Granulocyte Colony-Stimulating Factor (G-CSF)IBA
12/2016 - 06/2012
2Biomarkers (Surrogate Marker)IBA
02/2013 - 07/2010
2Topoisomerase II InhibitorsIBA
06/2012 - 12/2006
2Topoisomerase I InhibitorsIBA
06/2012 - 07/2010
2Vinorelbine (Navelbine)FDA LinkGeneric
04/2012 - 06/2005
27-ethyl-10-hydroxycamptothecin beta-glucuronideIBA
03/2012 - 10/2008
2GlucuronidaseIBA
03/2012 - 10/2008
2Hemoglobins (Hemoglobin)IBA
06/2009 - 01/2003
2CytokinesIBA
12/2008 - 04/2004
2Nitric Oxide (Nitrogen Monoxide)FDA Link
12/2008 - 04/2004
1BNT162 VaccineIBA
01/2023
1mRNA VaccinesIBA
01/2023
1Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA
07/2022
1AtropineFDA LinkGeneric
07/2022
1nimotuzumabIBA
01/2021
1Small Interfering RNA (siRNA)IBA
11/2019
1Immune Checkpoint InhibitorsIBA
11/2018
1B7-H1 AntigenIBA
11/2018
1osimertinibIBA
06/2018
1Glycoproteins (Glycoprotein)IBA
04/2018
1Basigin (Extracellular Matrix Metalloproteinase Inducer (EMMPRIN))IBA
04/2018

Therapy/Procedure

30Drug Therapy (Chemotherapy)
06/2019 - 06/2005
18Therapeutics
06/2019 - 06/2005
4Radiotherapy
01/2017 - 02/2007
3Adjuvant Chemotherapy
01/2020 - 01/2017
3Aftercare (After-Treatment)
01/2019 - 12/2006
2Chemoradiotherapy
01/2021 - 07/2017
2Cranial Irradiation
01/2018 - 09/2015
2Traction
01/2017 - 07/2011